Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Cymabay Therapeutics IncCBAY-38.11110.7110.53-28.85-46.64%-20.63%0.00(not set)$102.10-$32.48

Detail of Cymabay Therapeutics Inc

 
CEO
Mr. Sujal A. Shah
Employees
59
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B

Company details

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Revenue
Revenue (Rev)
$31.02M
Cymabay Therapeutics Inc
CBAY • XNGS • US
$32.48
+10.84 (50.09%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.85
Margin profit
-290.50%
52 week low
$22.155001
52 week high
$32.48
50-day simple moving average
$0.00
200-day simple moving average
$0.00
Percent held by insiders
0.27%
Percent held by institutions
98.68%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CBAY +47.44%
eps change
CBAY 0.00%